ORG – Page 10 – Talk Bio

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

3 weeks ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic

3 weeks ago talkbio0Tagged Autoantibodies, Autoimmune Diseases, Clinical Trials, Funding, GE8820, GlycoEra, Holdings, Immunoglobulin IgG4, Precision Immunology, protein degraders

GlycoEra; protein degraders; $130 million funding; autoimmune diseases; GE8820; IgG4 autoantibodies; Novo Holdings; clinical trial; precision immunology

About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds

3 weeks ago talkbio0Tagged Biological Factors, CBER, CDER, Drug Approval Process, drug review, layoffs, Staff, Trump administration, United States Food and Drug Administration

FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process

Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge

3 weeks ago talkbio0Tagged Cancer of Neck, Clinical Trials, Head, Keytruda, Merus, Overall Survival, pembrolizumab, Petosemtamab, Phase 2, Reaction, scenario

Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

3 weeks ago talkbio0Tagged ASCO, atezolizumab, IMforte trial, Jazz, lurbinectedin, Malignant neoplasm of lung, Overall Survival, Progression-Free Survival, Small cell carcinoma of lung, Tecentriq, Zepzelca

Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025

Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.

3 weeks ago talkbio0Tagged Beak, Budgets, CBO, healthcare changes, Medicare, reconciliation, Sequestration, Transplant Registry Unified Management Program

Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report

Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline

3 weeks ago talkbio0Tagged Acquisition, Agonist, Alzheimer 's disease, Microglia, Neurodegenerative Disorders, Phase 2 Trials, sanofi, TREM2, VG-3927, Vigil Neuroscience

Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals

HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets

3 weeks ago talkbio0Tagged biosimilar competition, branded drugs, CHARGE Syndrome, Country, Drug Industry, drug price, executive order, Generic competition, most-favored, Organisation for Economic Co-Operation and Development

most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries